Last reviewed · How we verify
Poor metabolisers
Poor metabolisers is not a drug but a pharmacogenetic classification describing individuals with reduced capacity to metabolize certain medications due to genetic variations in drug-metabolizing enzymes.
At a glance
| Generic name | Poor metabolisers |
|---|---|
| Sponsor | Radboud University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Poor metabolisers refers to a patient phenotype, not a therapeutic agent. It describes individuals who carry genetic variants (typically loss-of-function mutations) in cytochrome P450 enzymes or other metabolic pathways, resulting in significantly reduced drug clearance. This classification is used to guide personalized dosing and drug selection to prevent adverse events from drug accumulation.
Approved indications
Common side effects
Key clinical trials
- Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers (PHASE1)
- Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease. (PHASE4)
- Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women (PHASE1)
- A Healthy Volunteer Study With Inhaled GSK573719 and Placebo (PHASE1)
- Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome (PHASE4)
- Pharmacokinetic Interaction Between AZD3480 and Donepezil (PHASE1)
- Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects (PHASE1)
- To Compare Blood and Urine Concentrations of Mirabegron (YM178) in Healthy Poor or Extensive Metabolizers for CYP2D6 and to Assess the Effect of Mirabegron on the Metabolism of Metoprolol (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Poor metabolisers CI brief — competitive landscape report
- Poor metabolisers updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI